US4460577A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same
Assignee: Pfizer Italia SRL
•
Filing: 1980-01-14
•
Granted: 1984-07-17
•
Expires: 2000-01-14
Abstract
Abstract A method is disclosed for purifying non-homogeneous systems, known as liposomic suspensions, from non-entrapped drugs wherein said suspensions are treated with liquid or solid polymers of synthetic and organic nature having chemical functionality, which are used as ion-exchangers. The liquid or solid polymers are based on styrene, divinylbenzene, acrylic acid, methacrylic acid, and the like, normally known as ion-exchange resins, and may include carboxylic, phosphonic, or sulphonic functions of different matrices. The ion-exchange resins may also include salified quaternary ammonium, primary, secondary and tertiary amminic or phosphinic functions or other functions with different matrices, including phenolformaldehyde, styrene-divinylbenzene, acrylates, methacrylates, hydrocarbons and condensation-resins. Treatment may also be carried out with polymers, copolymers, or mixtures thereof, not having any specific chemical function and which normally, but not exclusively, react according to Van der Waals' forces, commonly known as adsorbents. The invention also includes pharmaceutical compositions consisting or consisting essentially of lyophilic liposomes of doxorubicin hydrochloride, aminosidine sulphate or 5-fluoro-uracil.
Inventors
- 👤 Luigi Moro
- 👤 Guido Neri
- 👤 Alessandro Rigamonti
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:35
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1277
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
60 words
A method for removing a non-entrapped drug from a liposomic suspension, comprising: (a) contacting said suspension with an ion-exchange resin capable of selectively binding said non-entrapped drug by mixing said suspension with said resin; and (b) separating said resin-bound drug from said suspension by passing said mixture through a filter medium capable of retaining said resin and filtrating said suspension.
Claim 2
Independent Claim
60 words
A method for removing a non-entrapped drug from a liposomic suspension, comprising: (a) contacting said suspension with an ion-exchange resin capable of selectively binding said non-entrapped drug by mixing said suspension with said resin; and (b) separating said resin-bound drug from said suspension by passing said mixture through a filter medium capable of retaining said resin and filtrating said suspension.
Claim 3
Dependent Claim
24 words
The method of claim 1 wherein said resin is selected from the group consisting of polymers of phenolformaldehyde, copolymers of styrene-divinylbenzene, acrylates and methacrylates.
Claim 4
Dependent Claim
32 words
The method of claim 1 wherein said ion-exchange resin is a liquid polymer based on at least one monomer selected from the group consisting of styrene, divinylbenzene, acrylic acid, and methacrylic acid.
Claim 5
Dependent Claim
32 words
The method of claim 1 wherein said ion-exchange resin is a solid polymer based on at least one monomer selected from the group consisting of styrene, divinylbenzene, acrylic acid, and methacrylic acid.
Claim 6
Dependent Claim
43 words
The method according to claim 3 or 4 wherein said ion-exchange resin is selected from the group consisting of weak strength, average strength, and strong strength cationic-type resins, said resins comprising functions selected from the group consisting of carboxylic, phosphonic, and sulfonic acids.
Claim 7
Dependent Claim
20 words
The method of claim 1 wherein said resin is selected from the group consisting of hydrocarbon resins, and condensation resins.
Claim 8
Dependent Claim
63 words
A method according to claim 1 wherein said ion-exchange resin is selected from the group consisting of weak strength and average strength anionic first and second type resins, said resins comprising functions selected from the group consisting of quaternary ammonium ions, primary, secondary and tertiary aminic and phosphinic functions appended to matrices selected from the group consisting of phenolformaldehyde, styrene-divinylbenzene, acrylates, and methacrylates.
Claim 9
Dependent Claim
19 words
The method of claim 7, wherein said matrices are selected from the group consisting of hydrocarbon and condensation resins.
Claim 10
Dependent Claim
16 words
A method according to claim 1 wherein said ion-exchange resin is in salified or activated form.
Claim 11
Independent Claim
76 words
A method for removing a non-entrapped drug from a liposomic suspension, comprising: (a) contacting said suspension with an adsorbent material capable of selectively adsorbing said non-entrapped drug in a nonionic chemical manner at least partially based on Van der Waals forces, by mixing said suspension with said adsorbent substance; and (b) separating said adsorbent-bound drug from said suspension by passing said mixture through a filter medium capable of retaining said adsorbent material and filtrating said suspension.
Claim 12
Independent Claim
76 words
A method for removing a non-entrapped drug from a liposomic suspension, comprising: (a) contacting said suspension with an adsorbent material capable of selectively adsorbing said non-entrapped drug in a nonionic chemical manner at least partially based on Van der Waals forces, by mixing said suspension with said adsorbent substance; and (b) separating said adsorbent-bound drug from said suspension by passing said mixture through a filter medium capable of retaining said adsorbent material and filtrating said suspension.
Claim 13
Dependent Claim
34 words
A method according to claim 10 wherein said adsorbent material is selected from the group consisting of aliphatic resins and aromatic resins having adsorbent properties at least partially due to Van der Waals forces.
Claim 14
Dependent Claim
17 words
The method of claim 1 or 11 further comprising a step: (c) stabilizing said filtrate by lyophilization.
References Cited (Backward Citations)
US3398092A
Cited
US3794584A
Cited
DE2249552A1
Cited
US3887698A
Cited
JPS5126213A
Cited
US3993754A
Cited
US4016100A
Cited
US4131544A
Cited
US4229360A
Cited
US4229360B1
Cited
US4145304A
Cited
US4298594A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-17 | 1988-01-16 | 1988-07-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-17 | 1992-01-16 | 1992-07-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-17 | 1996-01-16 | 1996-07-17 | $7700.00 | Window Closed / Lapsed |